© Reuters. Incyte earnings beat, first quarter revenue missing
Investing.com – Incyte (NASDAQ 🙂 reported Tuesday that analyst forecasts and sales were below expectations.
Incyte announced earnings per share of $ 0.67 on revenue of $ 604.7 million. Analysts polled by Investing.com expected earnings per share of $ 0.4617 on revenue of $ 662.22 million.
Incyte stocks are up 31% year-to-date, down 22.48% from their 52-week high of $ 110.32 on July 7, 2020. They outperform the S&P 500, which is up 11.62% year-to-date.
Incyte follows other major healthcare revenues this month
Incyte’s report follows a jump in earnings for J&J on April 20, which reported earnings per share of $ 2.59 on revenue of $ 22.32 billion, compared with forecast earnings per share of $ 2.34 on sales of $ 21.98 billion.
Pfizer exceeded expectations on Tuesday with earnings per share of $ 0.93 on sales of $ 14.58 billion, compared to a forecast for earnings per share of $ 0.7773 on sales of 13.67 billion . USD.
Stay up to date on all upcoming earnings reports by visiting Investing.com’s earnings calendar
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media, or anyone involved with Fusion Media, assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts, and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.